Bromocriptine and domperidone in the treatment of Parkinson disease
- 1 June 1981
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 31 (6) , 662
- https://doi.org/10.1212/wnl.31.6.662
Abstract
In a single-blind trial of therapy in 20 patients with idiopathic Parkinson disease, domperidone prevented nausea and vomiting induced by bromocriptine without diminishing beneficial central effects. Combination of the 2 drugs permitted rapid increase in bromocriptine dosage from 22.5 to 148 mg/day, with 71% mean clinical improvement over baseline score. Continuing efficacy of the regimen was evident for a mean follow-up of 2 mo.This publication has 9 references indexed in Scilit:
- THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASEThe Lancet, 1979
- BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING AGENT IN TREATMENT OF PARKINSON'S DISEASEThe Lancet, 1979
- Long-term treatment of Parkinson's disease with bromocriptine.Journal of Neurology, Neurosurgery & Psychiatry, 1979
- Bromocriptine in ParkinsonismArchives of Neurology, 1978
- Onset and End-of-Dose Levodopa-Induced DyskinesiasArchives of Neurology, 1978
- LONG-TERM TREATMENT OF PARKINSONISM WITH BROMOCRIPTINEThe Lancet, 1978
- Treatment of Parkinson's Disease with BromocriptineNew England Journal of Medicine, 1976
- EFFECT of CB 154 (2-BROMO-ALPHA-ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE-BLIND, CROSS-OVER TRIALActa Neurologica Scandinavica, 1976
- ParkinsonismNeurology, 1967